Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.97 |
| ▸ | HPGD | P15428 | 6/20 | 0.77 |
| ▸ | MMP13 | P45452 | 3/20 | 0.77 |
| ▸ | LMNA | P02545 | 3/20 | 0.77 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.77 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.77 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.77 |
| ▸ | TP53 | P04637 | 4/20 | 0.70 |
| ▸ | MEN1 | O00255 | 2/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.64 |
| ▸ | SPR | P35270 | 1/20 | 0.64 |
| ▸ | TSHR | P16473 | 1/20 | 0.64 |
| ▸ | MMP9 | P14780 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3536006 | 0.99 | MAPT (1.00) | MAPTHPGDMMP13LMNACYP1A2 | |
| SCHEMBL5190083 | 0.87 | MAPT (0.79) | MAPTHPGDMMP13LMNACYP1A2 | |
| SCHEMBL4381941 | 0.86 | MAPT (0.74) | MAPTHPGDMMP13LMNACYP1A2 | |
| SCHEMBL22066283 | 0.85 | MMP13 (0.74) | MAPTHPGDMMP13LMNACYP1A2 | |
| SCHEMBL22066297 | 0.81 | MMP13 (0.72) | MAPTHPGDMMP13LMNACYP1A2 | |
| SCHEMBL29943847 | 0.81 | HPGD (0.67) | MAPTHPGDMMP13LMNACYP1A2 | |
| SCHEMBL4375740 | 0.80 | HPGD (0.76) | MAPTHPGDMMP13LMNACYP1A2 | |
| SCHEMBL3583064 | 0.80 | MAPT (0.64) | MAPTHPGDMMP13LMNACYP1A2 | |
| SCHEMBL4379760 | 0.79 | HPGD (0.64) | MAPTHPGDMMP13LMNACYP1A2 | |
| SCHEMBL4373934 | 0.78 | HPGD (0.69) | MAPTHPGDMMP13LMNACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1263740-A1 | PYRIMIDINE-4-ONE DERIVATIVES AS LDL-PLA2 INHIBITORS | SmithKline Beecham plc (GB) | 2002-12-11 | — | — | EP | claimed |
| WO-2001060805-A1 | PYRIMIDINE-4-ONE DERIVATIVES AS LDL-PLA2 INHIBITORS | SMITHKLINE BEECHAM P.L.C. (GB) | 2001-08-23 | — | — | WO | claimed |
| US-8871775-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2014-10-28 | — | — | US | disclosed |
| US-20120172378-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2012-07-05 | — | — | US | disclosed |
| US-20100144765-A1 | 5,6-TRIMETHYLENEPYRIMIDIN-4-ONE COMPOUNDS | HICKEY DEIDRE MARY BERNADETTE | 2010-06-10 | — | — | US | disclosed |
| EP-1686119-B1 | Pyrimidine-5-one derivatives as LDL-PLA2 inhibitors | SMITHKLINE BEECHAM PLC (GB) | 2009-07-29 | — | — | EP | disclosed |
| US-20090170877-A1 | 5,6-Trimethylenepyrimidin-4-one compounds | SMITHKLINE BEECHAM P.L.C. | 2009-07-02 | — | — | US | disclosed |
| US-7470694-B2 | Treating atherosclerosis by administering 1-(N-(2-(diethylamino)ethyl)-N-(4-(4-trifluoromethylphenyl)benzyl)aminocarbonylmethyl)-2-(4-fluorobenzyl)thio-5,6-trimethylenepyrimidin-4-one or a salt; coadministering an anticholesterol agent; inhibitor of platlet activating factor acetylhydrolase | SMITHKLINE BEECHAM, PLC (GB) | 2008-12-30 | — | — | US | disclosed |
| US-20070155762-A1 | Treating atherosclerosis by administering 1-(N-(2-(diethylamino)ethyl)-N-(4-(4-trifluoromethylphenyl)benzyl)aminocarbonylmethyl)-2-(4-fluorobenzyl)thio-5,6-trimethylenepyrimidin-4-one or a salt; coadministering an anticholesterol agent; inhibitor of platlet activating factor acetylhydrolase | SMITHKLINE BEECHAM PLC | 2007-07-05 | — | — | US | disclosed |
| US-7232902-B2 | Process to prepare (1-carboxymethyl)-pyrimidinone compounds | SMITHKLINE BEECHAM P.L.C. (GB) | 2007-06-19 | — | — | US | disclosed |
| US-7153861-B2 | For therapy of atheroscelerosis | SMITHKLINE BEECHAM P.L.C. (GB) | 2006-12-26 | — | — | US | disclosed |
| EP-1686119-A1 | PYRIMIDINE-4-ONE DERIVATIVES AS LDL-PLA2 INHIBITORS | SMITHKLINE BEECHAM PLC (GB) | 2006-08-02 | — | — | EP | disclosed |
| EP-1263740-B1 | PYRIMIDINE-4-ONE DERIVATIVE AS LDL-PLA2 INHIBITOR | SMITHKLINE BEECHAM PLC (GB) | 2006-07-19 | — | — | EP | disclosed |
| EP-1456183-B1 | PROCESS FOR PREPARING 1-(CARBOXYMETHYL)-AND 1-(AMINOCARBONYL)-PYRIMIDIN-4-ONE DERIVATES | SMITHKLINE BEECHAM PLC (GB) | 2006-04-19 | — | — | EP | disclosed |
| US-20040242875-A1 | Novel processes | SMITHKLINE BEECHAM PLC (GB) | 2004-12-02 | — | — | US | disclosed |
| EP-1456183-A2 | PROCESS FOR PREPARING 1-(CARBOXYMETHYL)-AND 1-(AMINOCARBONYL)-PYRIMIDIN-4-ONE DERIVATES | SmithKline Beecham plc (GB) | 2004-09-15 | — | — | EP | disclosed |
| WO-2003016287-A2 | PROCESS FOR PREPARING 1-(CARBOXYMETHYL)- AND 1-(AMINOCARBONYL)- PYRIMIDIN-4-ONE DERIVATIVES | SMITHKLINE BEECHAM P.L.C. (GB) | 2003-02-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170877-A1 | 5,6-Trimethylenepyrimidin-4-one compounds | PLA2G4A, PLA2G4B, PLA2G1B | MAPT 4517/4885HPGD 471/4885MMP13 387/4885 |
| US-20120172378-A1 | NOVEL COMPOUNDS | PLA2G7, ALOX15B, PLA2G1B | MAPT 4738/4885HPGD 296/4885MMP13 1190/4885 |
| US-20070155762-A1 | Treating atherosclerosis by administering 1-(N-(2-(diethylamino)ethyl)-N-(4-(4-trifluoromethylphenyl)benzyl)aminocarbonylmethyl)-2-(4-fluorobenzyl)thio-5,6-trimethylenepyrimidin-4-one or a salt; coadministering an anticholesterol agent; inhibitor of platlet activating factor acetylhydrolase | PLAT, PLA2G7, LYPLAL1 | MAPT 4877/4885HPGD 355/4885MMP13 298/4885 |
| US-20040242875-A1 | Novel processes | DHPS, FDPS, NUDT5 | MAPT 3388/4885HPGD 662/4885MMP13 4862/4885 |
| US-20100144765-A1 | 5,6-TRIMETHYLENEPYRIMIDIN-4-ONE COMPOUNDS | PLA2G4A, PLA2G4B, PLA2G1B | MAPT 4517/4885HPGD 471/4885MMP13 387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.